These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 32442)
1. Pharmaceutical review: Ubretid - beta-carotene. Martin S Lamp; 1978 Nov; 35(11):37-9. PubMed ID: 32442 [No Abstract] [Full Text] [Related]
2. [Acute poisoning due to distigmine bromide]. Onodera M Chudoku Kenkyu; 2008 Apr; 21(2):161-7. PubMed ID: 18516941 [No Abstract] [Full Text] [Related]
3. Distigmine bromide (Ubretid) for the prevention of urinary retention after vaginal hysterectomy. Walsh J; Bonnar J J Obstet Gynaecol Br Commonw; 1972 Apr; 79(4):377-8. PubMed ID: 5025144 [No Abstract] [Full Text] [Related]
4. [Therapeutic results of a new anticholinesterase (Ubretid) used for myasthenia gravis in children]. Segawa M; Fukuyama S Nihon Shonika Gakkai Zasshi; 1967 May; 71(5):631-8. PubMed ID: 5624589 [No Abstract] [Full Text] [Related]
5. [Treatment of irritable bladder with Ubretid]. Mishina T Hinyokika Kiyo; 1970 Mar; 16(3):134-7. PubMed ID: 5462623 [No Abstract] [Full Text] [Related]
6. A further report on the effect of distigmine bromide (Ubretid) on the neurogenic bladder. Yeo J; Southwell P; Rutowski S; Marchant-Williams H Med J Aust; 1974 Aug; 2(6):201-3. PubMed ID: 4424051 [No Abstract] [Full Text] [Related]
7. Cholinesterase inhibitors in myasthenia gravis. Lange MJ Practitioner; 1966 Mar; 196(173):448-53. PubMed ID: 5905423 [No Abstract] [Full Text] [Related]
8. [Psychopharmacologically qualified side effects with distigmine bromide therapy (UBRETID, BC 51)]. Hertrich O Nervenarzt; 1976 May; 46(5):264-7. PubMed ID: 6920 [No Abstract] [Full Text] [Related]
9. [Treatment of dysuria with anticholinesterases: Ubretid]. Oka N; Hasegawa S Hinyokika Kiyo; 1967 Jan; 13(1):42-51. PubMed ID: 4169371 [No Abstract] [Full Text] [Related]
11. [Myasthenia gravis and pregnancy: review of the literature and report of 2 cases]. Cecatti JG; Pereira RI; Vial JS; Barini R Rev Paul Med; 1991; 109(1):41-6. PubMed ID: 1882173 [TBL] [Abstract][Full Text] [Related]
12. [Treatment of myasthenia gravis]. Igata A Naika; 1970 Apr; 25(4):676-82. PubMed ID: 5423420 [No Abstract] [Full Text] [Related]
14. beta-Carotene in the treatment of erythropoietic protoporphyria. A short review. Krook G; Haeger-Aronsen B Acta Derm Venereol Suppl (Stockh); 1982; 100():125-9. PubMed ID: 6819749 [TBL] [Abstract][Full Text] [Related]
16. Photosensitization by porphyrins and prevention of photosensitization by carotenoids. Mathews-Roth MM J Natl Cancer Inst; 1982 Jul; 69(1):279-85. PubMed ID: 6954320 [No Abstract] [Full Text] [Related]
17. [Use of Ubretid in the prevention of urine retention in the bladder following surgery for gynecologic diseases]. Kanadys W; Danelczyk W Ginekol Pol; 1978 Jun; 49(6):531-3. PubMed ID: 28996 [No Abstract] [Full Text] [Related]
18. The management of myasthenia gravis. Drug Ther Bull; 1977 Apr; 15(8):29-32. PubMed ID: 872734 [No Abstract] [Full Text] [Related]
19. Erythrohepatic protoporphyria and its treatment with beta-carotene. Krook G; Haeger-Aronsen B Acta Derm Venereol; 1974; 54(1):39-44. PubMed ID: 4135165 [No Abstract] [Full Text] [Related]
20. [Characteristics of childhood myasthenia gravis. 1. Electroencephalographic observation on childhood myasthenia gravis]. Segawa M; Nihei K Shinkei Kenkyu No Shimpo; 1971; 15(4):877-81. PubMed ID: 5168637 [No Abstract] [Full Text] [Related] [Next] [New Search]